KNSA
Kiniksa Pharmaceuticals Ltd
78.80$
+1.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -74.5% | -7.8% | +29.6% | -143.3% | – | +18.9% | +25.8% | +19.9% | +60.0% | -6.9% | -5.5% | – | |
| – | -60.9% | +97.5% | -7.7% | -7.2% | +0.3% | -13.7% | +3.8% | +7.3% | -11.7% | +422.1% | -68.1% | – | |
| – | +14.5% | -7.3% | +2.2% | +6.3% | +6.0% | -6.6% | +14.6% | +14.3% | -61.3% | +156.2% | +15.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -136.0% | – | -215.5% | – | +266.5% | -92.2% | -204.2% | – | – | -46.9% | -197.4% | – | |
| – | +250.0% | +50.0% | -100.0% | – | – | -48.7% | +66.7% | +306.7% | -5.7% | -74.6% | +311.8% | – | |
| – | +21.3% | – | -283.3% | -86.4% | – | -178.9% | -92.5% | +1,516.1% | +12.8% | -54.9% | +130.5% | – | |
| – | -76.3% | +45.4% | +244.6% | +106.5% | -78.7% | -28.7% | +396.8% | +112.7% | -78.9% | -65.6% | – | – | |
| – | +25.9% | +419.9% | -104.9% | – | -68.0% | +29.2% | +286.5% | +11.2% | -35.6% | -20.7% | -0.6% | – | |
| – | -287.7% | – | -226.2% | – | – | -130.7% | – | -149.2% | – | – | -182.5% | – | |
| – | -74.8% | -8.6% | +32.4% | -143.3% | – | +19.6% | +25.6% | +18.2% | +61.4% | -6.1% | -6.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.